ASCO 2026: Highlights from Day 1

Sunvozertinib Monotherapy versus Platinum-Based Chemotherapy as First-Line Treatment for Advanced NSCLC With EGFR Exon20ins: Primary Analysis of A Multinational Phase 3 Randomized Study (WU-KONG28)

• Sunvozertinib monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression‑free survival (PFS) compared with platinum‑based chemotherapy in treatment‑naïve advanced NSCLC with EGFR exon20ins mutations.
• Superior efficacy was observed across secondary endpoints, including higher objective response rate (ORR), longer duration of response (DoR), and improved disease control rate (DCR), with an overall favorable clinical benefit
• Sunvozertinib was generally well tolerated, with a manageable safety profile consistent with previous studies, supporting its role as a potential first‑line, chemo‑free targeted therapy option

Reference: LBA8500 – ASCO 2026

Mezigdomide, Carfilzomib, and Dexamethasone (MeziKd) vs Carfilzomib and Dexamethasone (Kd) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 SUCCESSOR-2 Trial

• Mezigdomide + carfilzomib + dexamethasone (MeziKd) demonstrated a statistically significant and clinically meaningful improvement in progression‑free survival (PFS) compared with carfilzomib + dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma 
• The combination showed favorable clinical benefit across key efficacy endpoints, with additional improvements expected in response‑related outcomes, supporting its potential role in patients previously treated with anti‑CD38 and lenalidomide 
• The safety profile of MeziKd was consistent with known toxicities of the regimen, with manageable adverse events, reinforcing its feasibility as an effective oral combination therapy in RRMM 

Reference: LBA7506 – ASCO 2026

A Phase III CHIPRO Study of Chiauranib plus Weekly Paclitaxel for Platinum-Resistant or Refractory Ovarian Cancer

• Chiauranib plus weekly paclitaxel is being evaluated in a randomized phase 3 (CHIPRO) study in platinum‑resistant or refractory ovarian cancer, targeting a population with high unmet clinical need and limited treatment options 
• Chiauranib, a novel multi‑target inhibitor (VEGFR, PDGFR, Aurora B, CSF‑1R), offers a multi‑pathway anti‑tumor mechanism including inhibition of angiogenesis, tumor proliferation, and immune modulation, supporting its potential to enhance chemotherapy efficacy 
• The study compares chiauranib + paclitaxel versus placebo + paclitaxel, assessing efficacy and safety outcomes, with maintenance chiauranib continued until disease progression in responding or stable patients 

Reference: LBA5504 – ASCO 2026

A Randomized, Open-label, Parallel-controlled phase 3 Trial of Benmelstobart plus Chemotherapy and Anlotinib for First-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

• Evaluated osimertinib alone vs. osimertinib plus local consolidative therapy (LCT) in metastatic EGFR-mutant NSCLC.
• Adding LCT to osimertinib improved progression-free survival and delayed disease progression compared to osimertinib alone.
• The combination strategy shows potential to enhance outcomes in EGFR-mutant NSCLC, supporting further investigation in larger trials

Reference: LBA8507- ASCO 2026

Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab (P) versus Pembrolizumab (P) as First-line Treatment for PD-L1-Positive Advanced Non-small Cell Lung Cancer (NSCLC): Results from the Randomized Phase 3 OptiTROP-Lung05 Study

• Sacituzumab tirumotecan (sac‑TMT) + pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in progression‑free survival (PFS) compared with pembrolizumab monotherapy in first‑line PD‑L1–positive advanced NSCLC, meeting the primary endpoint of the phase 3 OptiTROP‑Lung05 study 
• The combination showed enhanced clinical efficacy, including higher response rates and a positive trend in overall survival, indicating synergistic activity of the TROP2‑directed ADC with PD‑1 inhibition 
• The regimen represents the first phase 3 success of an antibody–drug conjugate combined with an immune checkpoint inhibitor in the first‑line NSCLC setting, with a manageable safety profile supporting further development 

Reference: Abs 8506- ASCO 2026

Lorlatinib vs Crizotinib as First-line Treatment for Advanced ALK+ Non-small Cell Lung Cancer: 7-year Update from the Phase 3 CROWN Study

• Lorlatinib demonstrated unprecedented long‑term efficacy versus crizotinib, with median progression‑free survival (PFS) not reached at 7‑year follow‑up compared with ~9.1 months for crizotinib, confirming sustained and clinically meaningful benefit in first‑line ALK+ NSCLC 
• Durable disease control was observed, with 7‑year PFS rates of ~55% vs 3%, indicating long‑lasting responses and a substantial proportion of patients remaining progression‑free on lorlatinib 
• Lorlatinib showed superior intracranial efficacy, with markedly prolonged time to brain progression and no new intracranial progression events after ~30 months, alongside a manageable long‑term safety profile

Reference: Abs 8502- ASCO 2026

Overall Survival of First-line Amivantamab plus Lazertinib in Atypical <em>EGFR</em>-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Updated Results from the CHRYSALIS-2 Study

• Amivantamab plus lazertinib demonstrated encouraging overall survival outcomes in patients with atypical EGFR‑mutated advanced NSCLC, reinforcing the potential of dual EGFR/MET targeting in this difficult‑to‑treat population
• The combination showed sustained clinical benefit beyond response rates, including durable disease control and improved survival across atypical EGFR mutation subgroups
• The safety profile remained manageable and consistent with prior studies, supporting continued development of this chemo‑free targeted combination strategy

Reference: Abs 8501- ASCO 2026

Safety and Efficacy of Elranatamab as Early Intervention in Patients with High-Risk Smoldering Myeloma: First Results from the Phase 2 ERASMM (EMN34) Study

• Elranatamab monotherapy demonstrated strong early anti‑tumor activity in high‑risk smoldering multiple myeloma, with a high overall response rate (~92%) and deep responses including ≥CR in ~45% of patients 
• Durable disease control was observed, with high short‑term progression‑free survival rates (~95% at 9 months), supporting the role of early intervention with BCMA‑targeted bispecific therapy  
• The safety profile was manageable, with predominantly low‑grade cytokine release syndrome (mostly grade 1–2), and no ICANS reported, although infections and other adverse events require monitoring 

Reference: Abs 7500- ASCO 2026

Overall Survival Subgroup Analyses for Prior Taxane Use in the Phase 3 ROSELLA Trial of Relacorilant plus Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023)

• Relacorilant plus nab‑paclitaxel demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with nab‑paclitaxel alone in platinum‑resistant ovarian cancer, with consistent benefit observed across patient subgroups 
• Subgroup analyses based on prior taxane exposure showed sustained survival benefit with the combination, supporting its efficacy irrespective of prior chemotherapy history 
• The combination maintained a manageable safety profile and represents a novel strategy targeting the glucocorticoid receptor to enhance chemotherapy sensitivity in a difficult‑to‑treat population 

Reference: Abs 5503- ASCO 2026

A Phase 2 Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients (pts) with Renal Cell Carcinoma (RCC) with Bone Metastases (BM): RADICAL (Alliance A031801)

• Radium‑223 dichloride combined with cabozantinib is being evaluated in the phase 2 randomized RADICAL (Alliance A031801) study to improve outcomes in renal cell carcinoma patients with bone metastases, a population with poor prognosis and high skeletal complication rates 
• The combination leverages complementary mechanisms—radium‑223 targeting bone metastases via alpha radiation and cabozantinib inhibiting VEGFR/MET pathways—with the aim of reducing symptomatic skeletal events and improving disease control 
• The trial assesses key endpoints including symptomatic skeletal event‑free survival (primary endpoint), along with PFS, OS, ORR, and safety, supporting its potential to enhance outcomes beyond standard cabozantinib therapy

Reference: Abs 4500 – ASCO 2026